explore -WSS

explore

author：leisure time 2025-09-14 10:04:15 - browse：71473

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： The problem with charging patients to message their doctors

WSS

How medical schools plan to diversify without affirmative action

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

What to make of Biden’s latest efforts on cancer research

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Former medical device CEO who sold dummy, plastic parts convicted of fraud

WATCH: Why do bright lights make us see spots?

entertainment

explore

explore

Bright Health sells Medicare Advantage business to Molina

How to bring more disabled researchers into academia

Dobbs anniversary: the lost opportunity of abortion as health care

Change Healthcare payments predicted restored March 15

State Dept. review finds Biden bears some blame for Afghanistan failures

Acelyrin, a rare IPO success, stumbles in its first big test

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Diverse clinical trials: Why aren’t we there yet?

leisure time

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Sen. Paul opposes bill to ban Chinese biotechs

IVF, abortion rights issues kick off Biden’s State of the Union

UnitedHealth quietly bought dozens of outpatient centers

Acelyrin, a rare IPO success, stumbles in its first big test

leisure time

focus

leisure time

explore